pre-IPO PHARMA

COMPANY OVERVIEW

IFM Therapeutics (IFM) is a privately held biopharmaceutical company that has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, auto-immunity, and inflammatory disorders.


LOCATION

  • Boston, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Fibrotic DIsease
  • Inflammatory Disease
  • Metabolic Disorders
  • Neurodegenerative Disease

  • WEBSITE

    https://www.ifmthera.com


    CAREER WEBSITE

    https://www.ifmthera.com/careers/


    SOCIAL MEDIA


    INVESTORS

    abingworth atlas-venture bms


    PRESS RELEASES


    Dec 1, 2021

    IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due


    Jan 7, 2020

    IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer


    Dec 2, 2019

    IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer


    Sep 5, 2019

    IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due


    May 8, 2019

    IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre


    For More Press Releases


    Google Analytics Alternative